Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269488 | 0.86 | PTPN1 (0.43) | PTPN1ACHE | |
| SCHEMBL269659 | 0.83 | ACHE (0.46) | PTPN1ACHE | |
| SCHEMBL16722810 | 0.82 | CES2 (0.46) | PTPN1GABBR2GABBR1GABRB1GABRB2 | |
| SCHEMBL269137 | 0.82 | PTPN1 (0.40) | PTPN1ACHEGABBR2GABBR1GABRB1 | |
| SCHEMBL284094 | 0.81 | ALDH1A1 (0.43) | PTPN1ACHE | |
| SCHEMBL269136 | 0.76 | MEN1 (0.35) | ACHEGABBR2GABBR1GABRB1GABRB2 | |
| SCHEMBL855617 | 0.75 | CES2 (0.61) | PTPN1GABBR2GABBR1GABRB1GABRB2 | |
| SCHEMBL20507035 | 0.74 | MEN1 (0.53) | CES2CES1CYP3A4 | |
| SCHEMBL10458011 | 0.74 | CYP2A6 (0.56) | CES2CES1CA2 | |
| SCHEMBL15745796 | 0.72 | ESR1 (0.48) | PTPN1ACHECES2CES1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | PTPN1 2258/4885ACHE 1793/4885GABBR2 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.